Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Efficacy of eptifibatide for treatment of severe dissections following percutaneous transluminal coronary angioplasty (PTCA) in small coronary arteries
Autore:
Haase, KK; Latsch, A; Suselbeck, T; Muth, N; Pfleger, S; Baumbach, A; Borggrefe, M;
Indirizzi:
Univ Klinikum Mannheim, Med Klin 1, D-68167 Mannheim, Germany Univ Klinikum Mannheim Mannheim Germany D-68167 -68167 Mannheim, Germany
Titolo Testata:
PERFUSION
fascicolo: 9, volume: 14, anno: 2001,
pagine: 330 -
SICI:
0935-0020(200109)14:9<330:EOEFTO>2.0.ZU;2-4
Fonte:
ISI
Lingua:
GER
Soggetto:
RISK-FACTORS; ABCIXIMAB; CLOSURE; STENTS; TRIAL;
Keywords:
PCI; GP IIb/IIIa inhibitors; eptifibatide; bail-out; vessel closure;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Haase, KK Univ Klinikum Mannheim, Med Klin 1, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany Univ Klinikum Mannheim Theodor Kutzer Ufer 1-3 Mannheim Germany D-68167
Citazione:
K.K. Haase et al., "Efficacy of eptifibatide for treatment of severe dissections following percutaneous transluminal coronary angioplasty (PTCA) in small coronary arteries", PERFUSION, 14(9), 2001, pp. 330

Abstract

It has been shown in several large trials, that the inhibition of glycoprotein IIb/IIIa receptors of platelets can reduce the rate of ischemic complications following percutaneous coronary interventions. We sought to determine the efficacy of eptifibatide in patients undergoing percutaneous transluminal coronary angioplasty (PTCA) in coronary arteries smaller than 2.5 mm who developed severe dissections with or without threatened vessel closure. From April 2000 until April 2001 36 of 693 patients undergoing percutaneous transluminal coronary angioplasty developed severe dissections, in whom eptifibatide was given as a bail-out procedure in a dosage of a bolus of 180mug/kg followed by an infusion of 2,0 mug/kg/min over 18 to 24 h. In all but two patients it was able to maintain antegrade flow, so that the additional placement of a coronary artery stent could be avoided. During the intrahospital stay three patients underwent repeat revascularization (2 Re-PTCAs, 1 ACVB-OP). There were no transmural myocardial infarctions and no death. Conclusion: The results of this prospective trial demonstrate hat eptifibatide is effective in maintaining antegrade flow in patients presenting withsevere dissections or threatened vessel closure following PTCA for symptomatic coronary artery disease in vessels smaller than 2.5 mm.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/07/20 alle ore 02:04:47